First Immunotherapy Treatment Guidelines Published for Hematologic and Prostate Cancers
December 21, 2016
SITC Lauds U.S. Senate Approval of 21st Century Cures Act
December 7, 2016
Society for Immunotherapy of Cancer Announces 2017 Richard V. Smalley, MD Memorial Lectureship Award Winner
December 5, 2016
First Kidney Cancer Treatment Guideline Published Focused on Immunotherapy
November 15, 2016
Society for Immunotherapy of Cancer Leads Discussion on how to Define the Value of Cancer Immunotherapy
November 14, 2016
Key scientific highlights from the 31st Annual Meeting of the Society for Immunotherapy of Cancer
November 13, 2016
Cutting-Edge Research on Cancer Immunotherapy Drugs and Combinations Presented at SITC 2016
November 10, 2016
Cancer Immunotherapy gets "CONNECTED" Through SITC's Innovative Community-Based Website
November 3, 2016
Society for Immunotherapy of Cancer to Convene 31st Annual Meeting
November 2, 2016
SITC Presidential Award Winner – David Clever – Published in Journal Cell
August 30, 2016
Society for Immunotherapy of Cancer Announces New Funding Opportunity for Cancer Immunotherapy Translational Fellowship
August 1, 2016
SITC launches new Initiative Non-small cell lung cancer immunotherapy: Advancing hope™
July 29, 2016
SITC to Host Virtual Cancer Moonshot Summit
June 28, 2016
SITC Announces Validation of Global Immune Biomarker Study
June 5, 2016
SITC Offering Fellowships Nearing $300,000 to Support Next Generation of Cancer Immunotherapy Researchers
February 11, 2016
SITC among First to Address Value Proposition of Cancer Immunotherapy
November 8, 2015
FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma
October 27, 2015
SITC Expands Global Reach, Elects Key Opinion Leaders to the Board
October 21, 2015
Expanded FDA Approval of Nivolumab: Game-Changing for Lung Cancer Patients and the Cancer Immunotherapy Field
October 15, 2015
New Immunotherapy for Lung Cancer Offers Hope to Patients, SITC Reacts
October 2, 2015
SITC Celebrates U.S. Food & Drug Administration Approval of First Combination Immunotherapy for the Treatment of Cancer
October 1, 2015
SITC Brings Immunotherapy Perspective, Leaders in the Field to Commission on Cancer
August 17, 2015
SITC Reacts to Approval of Pembrolizumab for Treatment of Metastatic Melanoma in Europe
July 27, 2015
Approval of Nivolumab for Treatment of Advanced Squamous Non-Small Cell Lung Cancer Brings New Hope to Patients in Europe
July 27, 2015
SITC Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma
June 29, 2015
SITC Announces Cancer Immunotherapy Clinical Fellowship Award Recipient
June 15, 2015
Immunotherapy Insights and Data Featured at ASCO Plenary Session
May 31, 2015
Late-Breaking Immunotherapy Abstract Session Attracts 6,000 Attendees at ASCO
May 30, 2015
FDA Approval of Nivolumab Life Changing for Patients, Paradigm Shifting for the Cancer Immunotherapy Field
March 6, 2015
SITC, Merck to Support Innovative Cancer Immunotherapy Research
January 26, 2015
SITC Leaders Weigh in on New Research Published in Nature
December 12, 2014
SITC Abstracts Now Available
November 6, 2014
Novel Strategies for Combining Cancer Immunotherapies Highlighted at SITC 2014
November 4, 2104
Immunologic Treatments for Non-Small Cell Lung Cancer Show Promise in Clinical Trials
November 4, 2104
SITC Reacts to FDA Approval of First PD-1 Blocking Drug for Melanoma
September 5, 2014
ASCO 2014 Concludes with Additional Promising Data for the Future of Cancer Immunotherapy
June 3, 2014
Data Presented at the ASCO Annual Meeting Expands the Field of Cancer Immunotherapy to Treat New Cancer Types
June 1, 2014
New Cancer Immunotherapy Fellowship Award Announced at Society for Immunotherapy of Cancer Annual Meeting
November 9, 2013
Don't Miss Key Scientific Meetings Covering the Major Advances in Cancer Immunotherapy
October 24, 2013
SITC Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy
August 27, 2013
SITC President Part of Team Reaching Bach2 in Cancer Immunotherapy Treatment
July 1, 2013
Melanoma Patients Receive Promising News Regarding Cancer Immunotherapy
Combination Treatment
June 1, 2013
SITC Members Participate in Rally for Medical Research to Support Cancer Immunotherapy
April 8, 2013
OPTiM Trial Results are First Positive Phase 3 OncologicalVirus Cancer Immunotherapy Study in Melanoma
March 22, 2013
Recent Discoveries in Cancer Immunotherapy Research Offer New Hope for Cancer Patients
October 25, 2012
SITC Leaders Publish Landmark Studies on New Cancer Immunotherapeutics
June 2, 2012
Researchers Honored at the Society for Immunotherapy of Cancer 26th Annual Meeting Awards Ceremony
November 7, 2011
New research on immune based therapies for cancer presented at the SITC 26th Annual Meeting & Associated Programs
November 4, 2011
FDA Approves Ipilimumab, Major Breakthrough in Cancer Immunotherapy
March 25, 2011
NIH Awards Major Funding to Support "Cancer Immunotherapy Trials Network"
October 4, 2010
Leading Cancer Immunotherapy Scientists and Research Teams Honored at iSBTc Annual Meeting
October 4, 2010
Major Advances in Cancer Immunotherapy Highlighted at Key Scientific Meetings in Washington, D.C.
September 23, 2010
Cancer Immunotherapies Coming of Age
June 8, 2010
Immunotherapy Breakthrough for Cancer Patient Treatment
June 6, 2010
FDA Approval of New Prostate Treatment Shows Promise of Cancer Immunotherapy
April 29, 2010
